Sai Life Sciences Limited

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes dapsone. Therapeutic category: anti bacterial. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes doxercalciferol. Therapeutic category: vit D. Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes enzalutamide. Chemical name: 4-((2-cyanopropan-2-yl)amino) -2-fluoro-N-methylbenzamide. Contact us for more information.

Sai Life Sciences Limited offers a wide range of active pharmaceutical ingredients which includes epoprostenol. Therapeutic category: prostaglandin. Contact us for more information.

Sai Life Sciences Limited offers a wide range of intermediates which includes fexofenadine hcl. Chemical name: methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate – - (fexofenadine methyl ester). Contact us for more information.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the appointment of Sauri Gudlavalleti as its Chief Operating Officer. Sauri will report to the CEO & Managing Director, Krishna Kanumuri and drive the company’s growth as a new generation, science-driven organization.

Sai Life Sciences today announced the release of its 2021 Sustainability Report. 

Sai Life Sciences today commenced recruitment for 100+ scientific positions across medicinal chemistry and biology to bolster the company’s growth plans of achieving scale, scope and speed in its Discovery business. All positions will be based at the company’s Integrated Research & Development campus in Hyderabad, India.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of Inspection. 

Sai Life Sciences won the LearnX Live Award, Australia, under the category Best Learning Technology, making it the fifth Learning & Development award for the company in the year.

In a global assessment acknowledged as a gold standard by procurers and suppliers, winning a silver is gratifying. 

Sai Life Sciences, a global CRO & CDMO offering sustainable solutions to pharmaceutical companies through strategic partnerships and integrated drug discovery and development services, has been awarded with ‘Excellent Energy Efficient Unit’ in the general category at CII’s 22nd National Energy Management Awards. 

At its first ever participation in the awards, Sai Life Sciences won the Environmental Supplier award 2021 in the ‘Primary Manufacturing’ category.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that it has become a signatory of the United Nations Global Compact (UNGC), the world’s largest sustainability initiative. 

Sai Life Sciences won the Gold Award in Brandon Hall Group Excellence Awards under the “Best Advance in Learning Technology Implementation” category.

 

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the opening of a new biology facility at its integrated R&D campus in Hyderabad, India. The facility marks an important milestone in the journey of positioning itself as a differentiated player in Discovery Biology.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced that it has been honoured with the Golden Peacock National Training Award 2021 in the pharmaceutical category. This is the second consecutive Golden Peacock Award for the company following the Golden Peacock National Quality Award it received in 2020.